CareDx 배당 및 자사주 매입
배당 기준 점검 0/6
CareDx 배당금을 지급한 기록이 없습니다.
핵심 정보
n/a
배당 수익률
8.4%
자사주 매입 수익률
| 총 주주 수익률 | 8.4% |
| 미래 배당 수익률 | 0% |
| 배당 성장률 | n/a |
| 다음 배당 지급일 | n/a |
| 배당락일 | n/a |
| 주당 배당금 | n/a |
| 배당 성향 | n/a |
최근 배당 및 자사주 매입 업데이트
Recent updates
내러티브 업데이트 • Apr 27
CDNA: Wider 2026 Revenue Outlook And CMS Overhang Will Drive Repricing
Analysts have raised their average price target on CareDx by $1 to $26 per share, citing a solid Q4, a wide but above-consensus 2026 revenue outlook, and a view that the stock still appears inexpensive even with ongoing uncertainty around the CMS outcome. Analyst Commentary Recent Street commentary highlights a mix of optimism around CareDx's execution and revenue outlook, alongside ongoing caution tied to policy risk.Seeking Alpha • Apr 18
CareDx: Watch For Profit-Taking After Recent Positive Preliminary Q1 Results
Summary CareDx is a leading precision medicine company specializing in transplant diagnostics, recently divesting its lab products portfolio for $170 million to focus on core testing services. CDNA demonstrates solid revenue growth and improving gross margins, but faces stiff competition from Natera, limited differentiation, and ongoing regulatory headwinds. Despite positive cash flow and a low debt/equity ratio, risks include declining R&D spending, falling book value, insider selling, and policy uncertainty that could impact revenue. I maintain a Hold rating on CDNA, viewing shares as attractive below $18, but prefer Natera for growth-oriented investors given its stronger momentum and market position. Read the full article on Seeking Alpha내러티브 업데이트 • Apr 13
CDNA: Wider 2026 Guide And CMS Overhang Will Drive Repricing
Analysts have lifted their price target on CareDx by $1 to $26, citing a solid Q4, a 2026 revenue outlook set above Street estimates, and a view that shares look inexpensive even with ongoing CMS uncertainty. Analyst Commentary Street research points to a mixed but generally constructive view on CareDx, with analysts weighing a solid recent quarter and new long term revenue guidance against ongoing policy risks and execution questions.
내러티브 업데이트 • Mar 30
CDNA: Final MolDX LCD Decision Will Drive 2026 Outlook And Upside Potential
Narrative Update on CareDx Analysts have raised their implied fair value estimate for CareDx to $21.00 from $20.00. This reflects updated views on 2026 revenue guidance, reimbursement uncertainty and the stock's valuation relative to recent Street research commentary.내러티브 업데이트 • Mar 16
CDNA: Wider 2026 Outlook And CMS LCD Overhang Will Drive Repricing
The analyst price target for CareDx has shifted from $23 to $24.80, as analysts balance a wider 2026 revenue outlook and recent Q4 performance against ongoing uncertainty around the final CMS LCD and its impact on long term growth. Analyst Commentary Recent Street commentary reflects a split view on CareDx, with some analysts focusing on upside tied to execution and valuation, while others emphasize uncertainty around reimbursement and longer term growth.내러티브 업데이트 • Mar 02
CDNA: Final MolDX LCD Outcome Will Shape Appeal Despite 2026 Guidance
The analyst price target for CareDx has been raised from $18 to $20. Analysts point to a higher assumed revenue growth outlook, a slightly higher future P/E, and management's 2026 revenue guidance, while still flagging uncertainty around the final CMS LCD and its impact on longer term growth and volumes.내러티브 업데이트 • Feb 16
CDNA: MolDX LCD Outcome Will Temper Appeal Despite Solid 2025 Guidance
Analysts have lowered their outlook on CareDx, reducing the price target to $26. They see a less compelling risk reward profile given uncertainty around the final MolDX LCD and how it could affect 2026 revenue, longer term growth, and near term test volumes.
내러티브 업데이트 • Feb 01
CDNA: Reimbursement Outcomes Will Drive Future Upside Despite Cautious Rating
Analysts have trimmed their fair value estimate for CareDx from US$28 to US$26, citing a less compelling risk reward outlook as revenue and longer term growth now appear more closely tied to uncertain reimbursement outcomes and a much higher assumed future P/E. Analyst Commentary Recent research points to a more cautious stance on CareDx, with the key concern being how much future revenue and growth now hinge on reimbursement decisions and a higher assumed future P/E multiple.내러티브 업데이트 • Jan 18
CDNA: MolDX LCD Uncertainty Will Restrain Appeal Despite Raised Guidance
Narrative Update on CareDx The analyst price target for CareDx has been reset to US$18.00. This reflects what analysts see as a less compelling risk reward profile, given uncertainty around future revenue tied to the final MolDX LCD and the possibility that upcoming estimates and longer term growth expectations may be too optimistic.내러티브 업데이트 • Jan 04
CDNA: Raised Guidance And Share Buyback Will Shape Balanced Outlook
Analysts have raised their price target on CareDx from 14 dollars to 18 dollars, citing expectations for stronger revenue growth and a higher future earnings multiple, despite a modestly higher discount rate and lower projected profit margins. What's in the News Shareholder derivative lawsuits against current and former directors are moving toward a proposed global settlement, with a final approval hearing scheduled for June 30, 2026 in the U.S. District Court for the Northern District of California (shareholder litigation notice).내러티브 업데이트 • Dec 17
CDNA: Raised Revenue Outlook And Buyback Activity Will Support Bullish Repricing
Analysts have nudged their price target on CareDx higher from around 21.83 dollars to 23.00 dollars, citing expectations for slightly faster revenue growth and a richer future valuation multiple, despite a more conservative view on long term profit margins and discount rates. What's in the News The board amended and restated company bylaws to adopt a majority voting standard for director elections, with plurality voting only in contested elections (company bylaws filing).분석 기사 • Nov 29
CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 25% But Its Business Still Trails The Industry
CareDx, Inc ( NASDAQ:CDNA ) shares have continued their recent momentum with a 25% gain in the last month alone...분석 기사 • Nov 12
We Believe CareDx's (NASDAQ:CDNA) Earnings Are A Poor Guide For Its Profitability
CareDx, Inc ( NASDAQ:CDNA ) recently released a strong earnings report, and the market responded by raising the share...분석 기사 • Sep 19
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Those holding CareDx, Inc ( NASDAQ:CDNA ) shares would be relieved that the share price has rebounded 28% in the last...분석 기사 • Aug 27
Calculating The Intrinsic Value Of CareDx, Inc (NASDAQ:CDNA)
Key Insights The projected fair value for CareDx is US$10.87 based on 2 Stage Free Cash Flow to Equity Current share...내러티브 업데이트 • Aug 15
Rising Organ Transplant Needs Will Reshape Diagnostics Despite Challenges
CareDx’s consensus price target was reduced from $27.50 to $22.20, primarily due to heightened reimbursement risk stemming from the proposed Palmetto MolDx LCD and recent share price volatility, despite operational stability and some analysts seeing undervaluation at current levels. Analyst Commentary Ongoing uncertainty surrounding the Palmetto MolDx draft Local Coverage Determination (LCD), which proposes to limit reimbursement for certain transplant tests.분석 기사 • Jul 23
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 32%
The CareDx, Inc ( NASDAQ:CDNA ) share price has fared very poorly over the last month, falling by a substantial 32...분석 기사 • May 02
Is There An Opportunity With CareDx, Inc's (NASDAQ:CDNA) 28% Undervaluation?
Key Insights The projected fair value for CareDx is US$20.92 based on 2 Stage Free Cash Flow to Equity Current share...
새 내러티브 • Mar 24
AlloMap Testing And OPTN Project Will Expand Markets Despite Risks
CareDx's growth fueled by expanded testing services and strategic investments aims to improve margins and revenue cycle management.Seeking Alpha • Mar 13
CareDx: Some Litigation Clouds Have Cleared
Summary CareDx, Inc. has cleared up some litigation and legal challenges since I last looked at this diagnostic concern last summer. The company continues to post solid revenue growth and has a rock-solid balance sheet. FY2024 saw progress on numerous fronts, and CDNA delivered margin increases and a massive increase in adjusted EBITDA. An updated analysis around CareDx, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Mar 11
Why CareDx's (NASDAQ:CDNA) Earnings Are Weaker Than They Seem
We didn't see CareDx, Inc's ( NASDAQ:CDNA ) stock surge when it reported robust earnings recently. We decided to have a...Seeking Alpha • Dec 30
CareDx: Too Risky For Me
Summary CareDx faces regulatory challenges and lacks a durable competitive advantage in a fragmented and competitive market, with no clear moat to protect its position, leading to a poor risk-reward profile. Management changes and negative employee reviews indicate potential internal instability, casting doubt on future company performance despite their innovative products. Despite strong gross margins and a solid balance sheet, CareDx's inability to turn a profit and questionable capital allocation methods make it a sell. Read the full article on Seeking Alpha분석 기사 • Nov 05
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%
CareDx, Inc ( NASDAQ:CDNA ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Sep 29
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
Summary CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives. Despite ongoing legal disputes with Natera, revised processes may protect future AlloSure revenues. CDNA's valuation is high, but its expanding revenues and recent insurance coverage wins justify a "Buy" rating for investors aware of inherent biotech risks. Read the full article on Seeking Alpha분석 기사 • Aug 01
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Despite an already strong run, CareDx, Inc ( NASDAQ:CDNA ) shares have been powering on, with a gain of 34% in the last...Seeking Alpha • Jul 15
CareDx: Benefiting From Some Certainty
Summary Today, we circle back to diagnostic testing concern CareDx, Inc for the first time in 2024. The stock has moved up some 60% since the company delivered better than expected quarterly results in early May. The company has appointed a new CEO and seen some certainty around a key patent litigation lawsuit so far this year as well. Can the rally continue, or is the stock overdue for some profit taking? An updated analysis follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Apr 27
Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge
CareDx, Inc ( NASDAQ:CDNA ) shares have had a horrible month, losing 28% after a relatively good period beforehand. The...분석 기사 • Mar 02
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
CareDx, Inc ( NASDAQ:CDNA ) shareholders would be excited to see that the share price has had a great month, posting a...분석 기사 • Dec 27
CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry
CareDx, Inc ( NASDAQ:CDNA ) shares have continued their recent momentum with a 26% gain in the last month alone. Taking...분석 기사 • Dec 27
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Despite an already strong run, CareDx, Inc ( NASDAQ:CDNA ) shares have been powering on, with a gain of 26% in the last...지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: 과거에 CDNA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.
배당금 증가: CDNA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.
배당 수익률 vs 시장
| CareDx 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (CDNA) | n/a |
| 시장 하위 25% (US) | 1.4% |
| 시장 상위 25% (US) | 4.2% |
| 업계 평균 (Biotechs) | 2.5% |
| 분석가 예측 (CDNA) (최대 3년) | 0% |
주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CDNA 의 배당 수익률을 평가할 수 없습니다.
고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CDNA 의 배당 수익률을 평가할 수 없습니다.
주주 대상 이익 배당
수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CDNA 의 지급 비율을 계산하기에는 데이터가 부족합니다.
주주 현금 배당
현금 흐름 범위: CDNA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/11 12:13 |
| 종가 | 2026/05/08 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
CareDx, Inc.는 14명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |